- Atreca’s Immune Repertoire Capture® Platform Generates Potent Antibodies Targeting Multiple Tumor Types
- Atreca Antibody Eliminates Tumor in In Vivo Preclinical Model
REDWOOD CITY, CA, USA I February 22, 2017 I Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep understanding of the human immune response, announced today the presentation of positive preclinical findings in its immuno-oncology program, generated via the Company’s Immune Repertoire Capture® (IRC™) technology platform. Atreca’s IRC™ technology identifies and generates sequences of native antibodies and T cell receptors (TCRs) from active human immune responses, including natively paired and complete variable regions of receptors expressed by specifically selected B- and T-cells. New findings from Atreca’s lead program are being highlighted at the 24th annual Molecular Medicine Tri-Conference, taking place at the Moscone North Convention Center in San Francisco, CA, February 19-24, 2017.
In a presentation, titled “The Immune Repertoire Capture™ (IRC™) Technology Platform,” Daniel Emerling, Ph.D., Atreca’s Senior Vice President, Research, is presenting key preclinical findings today at 12:10 p.m. Pacific Time, including:
- Atreca’s researchers have used IRC™ technology to generate functional antibodies from the active immune response of individuals with metastatic disease who experienced a response to therapy.
- Several patient-derived antibodies have been shown to bind tumor tissue but not normal tissue, and some antibodies bind multiple tumor types, including lung and breast adenocarcinoma, and renal cell carcinoma.
- In a preclinical syngeneic in vivo tumor model, administration of the human variable regions derived from a particular patient antibody (linked to a mouse constant region) resulted in clearance of tumor in a majority of the animals, with concomitant infiltration of immune system cells into tumor tissue. Potential synergy with a checkpoint inhibitor was also observed.
“We are thrilled with the continued momentum of our programs based on successful anti-tumor immune responses in cancer patients undergoing treatment,” stated N. Michael Greenberg, PhD, Atreca’s Chief Scientific Officer. “Our most recent data validate our next-generation approach in monotherapy as well as combination therapy, potentially addressing the substantial need to enhance patient responses to checkpoint inhibition. The unique features and capabilities of our platform allow us to pursue diverse applications outside of cancer as well, and we look forward to our progress as we advance toward IND-enabling studies in our lead program.”
Atreca applies IRC™ to generate sequences of native antibodies and TCRs from cancer patients who have responded well to immunotherapy and other treatments, patients with autoimmune disease, vaccinated subjects, and patients who resolve infections. Analyses of the resulting essentially unbiased and error-free repertoires yield insights into immunology, as well as potent antibodies targeting tumors, pathogens, and autoimmune epitopes.
About Atreca, Inc.
Atreca is a privately held biotechnology company developing novel therapeutics drawn from human immune responses, including effective anti-cancer immune responses. We are able to measure and analyze the structure of clinically relevant immune responses to identify the antibodies, T cell receptors, and targets that are key to successful treatment outcomes. Atreca’s proprietary Immune Repertoire Capture™ technology profiles a patient’s immune response at the single-cell level at very high throughput without bias or error, enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen. The Company is advancing a pipeline of candidates with the objective of enhancing engagement of the human immune response in cancer treatment and other indications, thus optimizing therapeutic outcomes. For more information on Atreca, please visit www.atreca.com.
SOURCE: Atreca
